Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Maxigen Biotech stock price, quote, forecast and news

1783.TW
TW0001783009

Price

45.00
Today +/-
-0.03
Today %
-2.41 %
P

Maxigen Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Maxigen Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Maxigen Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Maxigen Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Maxigen Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Maxigen Biotech Stock Price History

DateMaxigen Biotech Price
9/4/202445.00 undefined
9/3/202446.10 undefined
9/2/202446.55 undefined
8/30/202446.55 undefined
8/29/202446.55 undefined
8/28/202446.55 undefined
8/27/202446.50 undefined
8/26/202446.10 undefined
8/23/202446.10 undefined
8/22/202445.60 undefined
8/21/202445.10 undefined
8/20/202444.05 undefined
8/19/202443.80 undefined
8/16/202443.20 undefined
8/15/202443.20 undefined
8/14/202443.20 undefined
8/13/202443.10 undefined
8/12/202442.75 undefined
8/9/202442.00 undefined
8/8/202441.50 undefined

Maxigen Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Maxigen Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Maxigen Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Maxigen Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Maxigen Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Maxigen Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Maxigen Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Maxigen Biotech’s growth potential.

Maxigen Biotech Revenue, EBIT and net profit per share

DateMaxigen Biotech RevenueMaxigen Biotech EBITMaxigen Biotech Net Income
2023622.12 M undefined149.85 M undefined165.83 M undefined
2022604.43 M undefined128.62 M undefined139.4 M undefined
2021511.98 M undefined89.95 M undefined87.67 M undefined
2020457.69 M undefined61.11 M undefined63.31 M undefined
2019452.2 M undefined65.62 M undefined60.11 M undefined
2018427.68 M undefined46.19 M undefined57.06 M undefined
2017427.56 M undefined21.05 M undefined15.79 M undefined
2016336.39 M undefined-11.31 M undefined-12.25 M undefined
2015261.47 M undefined-60.52 M undefined-62.96 M undefined
2014245.69 M undefined-28.6 M undefined-19.04 M undefined
2013232.9 M undefined-3.6 M undefined2.6 M undefined
2012222 M undefined-10.8 M undefined2.7 M undefined
2011178.9 M undefined-41.6 M undefined-36.1 M undefined
2010172.4 M undefined-30.9 M undefined-16 M undefined
2009180.6 M undefined7.3 M undefined12.6 M undefined
2008123.2 M undefined-31.5 M undefined-34.3 M undefined

Maxigen Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2008200920102011201220132014201520162017201820192020202120222023
123180172178222232245261336427427452457511604622
-46.34-4.443.4924.724.505.606.5328.7427.08-5.851.1111.8218.202.98
25.2043.8937.2128.6545.5046.1239.1834.8739.8837.4742.6248.0146.8351.0861.7568.17
317964511011079691134160182217214261373424
-317-30-41-10-3-28-60-112146656189128149
-25.203.89-17.44-23.03-4.50-1.29-11.43-22.99-3.274.9210.7714.3813.3517.4221.1923.95
-3412-16-3622-19-62-121557606387139165
--135.29-233.33125.00-105.56--1,050.00226.32-80.65-225.00280.005.265.0038.1059.7718.71
50.550.549.95151.860.970.1370.776.7676.4785.3283.6680.6384.0689.4189.45
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Maxigen Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Maxigen Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2008200920102011201220132014201520162017201820192020202120222023
                               
100.3190.6273.9203.6203.1519.17354.710354.71305.27381.91419.78209.77540.18801.26432.58
22.631.246.938.548.852.6682.21082.21101.5362.9173.3359.3562.3271.0273.46
8.113.212.21413.323.8630.4030.458.2723.6532.8940.9152.0829.0623.6
38.334.541.150.257.393.7591.04091.0493.9882.6288.1286.9878.9575.2785.19
15.917.853.67.611.31013.115.6514.2948.4426.0435.0550.0216.634.74
185.2287.3379.1309.9330.1700.75558.3613.1574.01573.33599.53640.15432.06783.55993.25619.56
34.133.430155.7156.6446503.190503.19502.05494.03502.09481.52465.45437.1430.05
5.7009.29.19.059.0109.018.988.958.928.898.868.83432.8
000000000000001.220
1.71.20.72.60.934.1804.182.712.592.241.671.831.160.49
0000000000000000
16.921.619.99.59.37.657.0107.0116.9130.3732.0932.335.497.3910.09
58.456.250.6177175.9465.7523.40523.4530.65535.93545.33524.41481.63455.7873.42
0.240.340.430.490.511.171.080.011.11.11.141.190.961.271.451.49
                               
411.2411.2501.2506.2512.8708.47708.470708.47708.47708.47694.65694.65769.99846.99889.34
00.493.25.36.7184.361210121108.51108.5189.1889.18264.39281.9296.1
-196.4-183.7-199.7-144.2-141.7-63.36-12.490-12.4915.5562.2370.4279.38110.3169.8245.41
0.885.10.71.97.60.39-2.450-2.45-3.12-3.08-2.93-2.99-2.96-3.04-2.46
000000000000000-67.28
0.220.310.40.370.390.830.8100.810.830.880.850.861.141.31.36
12.513.814.116.815.123.9533.77033.7740.513133.973340.1535.9417.17
9.613.814.10025.9125.91031.3833.0143.8648.2536.6440.3555.3564.63
5.82.96.120.925.47.3120.92020.927.83217.54237.1714.4533.260.2149.58
0000000000000000
000006.171.6101.611.6402.562.492.3600
27.930.534.337.740.563.3482.21087.6882.98292.39321.9586.58116.07151.5131.37
0008080272.94224.60224.6224.66012.139.647.2800
00000000000000547491
0.10.10.10.10.12.113.7603.760.090.090.090.020.120.020.02
0.10.10.180.180.1275.04228.360228.36224.740.0912.229.667.40.570.51
2830.634.4117.8120.6338.39310.570316.03307.73292.48334.1796.24123.47152.07131.88
0.240.340.430.490.511.171.1301.131.141.171.190.961.271.451.49
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Maxigen Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Maxigen Biotech's financial health and stability.

Assets

Maxigen Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Maxigen Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Maxigen Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Maxigen Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200820092010201120122013201420152016201720182019202020212022
-3412-16-3623-18-62-111657727697165
101011147661218252632333229
001,000000000000000
19-4-16-585-341-5925786-9-34-1759
712221-40310-10513
000011111000800
00000000000016810
319-16-7618-22-14-10934511709474117268
-7-7-6-138-7-58-130-127-72-29-20-23-11-15-11
-18-147-149-47-221-252137-14140-14242139-210
-10-713-10-39-163-121265-6969-122661501222
000000000000000
0008000-2-6-54-1-14-2-2-20
084956124970223-3300002470
0849586124973219-86-5-25-54-271188-1
00000001,0001,000-3,00000-214,00000
0000000000-10-51-54-560
-148886-138-16253-263247-19685282-57303277
-3.811.7-22.8-215.111.2-80.3-145.44-237.09-37.9922.42150.3670.6863.06102.15256.37
000000000000000

Maxigen Biotech stock margins

The Maxigen Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Maxigen Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Maxigen Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Maxigen Biotech's sales revenue. A higher gross margin percentage indicates that the Maxigen Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Maxigen Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Maxigen Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Maxigen Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Maxigen Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Maxigen Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Maxigen Biotech Margin History

Maxigen Biotech Gross marginMaxigen Biotech Profit marginMaxigen Biotech EBIT marginMaxigen Biotech Profit margin
202368.17 %24.09 %26.66 %
202261.88 %21.28 %23.06 %
202150.98 %17.57 %17.12 %
202046.87 %13.35 %13.83 %
201948.05 %14.51 %13.29 %
201842.69 %10.8 %13.34 %
201737.49 %4.92 %3.69 %
201640.11 %-3.36 %-3.64 %
201535.01 %-23.15 %-24.08 %
201439.1 %-11.64 %-7.75 %
201346.03 %-1.55 %1.12 %
201245.77 %-4.86 %1.22 %
201128.51 %-23.25 %-20.18 %
201037.41 %-17.92 %-9.28 %
200943.74 %4.04 %6.98 %
200825.73 %-25.57 %-27.84 %

Maxigen Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Maxigen Biotech earnings per share therefore indicates how much revenue Maxigen Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Maxigen Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Maxigen Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Maxigen Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Maxigen Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Maxigen Biotech Revenue, EBIT and net profit per share

DateMaxigen Biotech Sales per ShareMaxigen Biotech EBIT per shareMaxigen Biotech Earnings per Share
20236.95 undefined1.68 undefined1.85 undefined
20226.76 undefined1.44 undefined1.56 undefined
20216.09 undefined1.07 undefined1.04 undefined
20205.68 undefined0.76 undefined0.79 undefined
20195.41 undefined0.78 undefined0.72 undefined
20185.01 undefined0.54 undefined0.67 undefined
20175.59 undefined0.28 undefined0.21 undefined
20164.38 undefined-0.15 undefined-0.16 undefined
20153.7 undefined-0.86 undefined-0.89 undefined
20143.5 undefined-0.41 undefined-0.27 undefined
20133.82 undefined-0.06 undefined0.04 undefined
20124.29 undefined-0.21 undefined0.05 undefined
20113.51 undefined-0.82 undefined-0.71 undefined
20103.45 undefined-0.62 undefined-0.32 undefined
20093.58 undefined0.14 undefined0.25 undefined
20082.44 undefined-0.62 undefined-0.68 undefined

Maxigen Biotech business model

Maxigen Biotech Inc is a biotechnology company that was founded in 2000. The company, based in San Francisco, California, specializes in the development and production of biotechnological products and solutions. The company's goal is to lead in the biotechnology industry and have a positive impact on the health and well-being of people. To achieve its goals, the company has specialized in four business areas. The first business area is the research and development of new biotechnological products. The company has a team of scientists who work continuously on new innovative technologies and products. The company has already brought several products to market that have been very successful in the biotechnology industry. The second business area is the production of biotechnological products. The company has its own production facility equipped with state-of-the-art technologies. Here, the company's products are manufactured and delivered to customers worldwide. The third business area is the distribution of biotechnological products. The company has built a large distribution network to distribute its products in different parts of the world. The company works closely with pharmacies, laboratories, and hospitals to ensure that its products are made accessible to people. The fourth business area is the application of biotechnological products. The company works closely with doctors and healthcare facilities to ensure that its products are used in medical practice. The company is committed to using its products to improve the health and well-being of people worldwide. Maxigen Biotech Inc has introduced some remarkable products to the market in its history. One of the company's most important products is a highly effective antibiotic used to fight bacterial infections. The company has also developed a medication for the treatment of hypertension that is in high demand worldwide. Additionally, the company has developed a range of products for the treatment of cancer and other serious illnesses. The company has also made a significant contribution to public health. The company has developed technology to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. The company has also worked on the development of vaccines against infectious diseases that are still prevalent in some regions of the world. Maxigen Biotech Inc has received numerous awards and recognition in its history. The company is known for its innovation and high quality in the production of its products. The company is an example of how the biotechnology industry can contribute to improving the health and well-being of people worldwide. In summary, Maxigen Biotech Inc is a biotechnology company that specializes in the development and production of biotechnological products and solutions. The company has specialized in four business areas: research and development of new products, production of biotechnological products, distribution of biotechnological products, and application of biotechnological products. The company has introduced some remarkable products to the market in its history and has made a significant contribution to public health. The company has received numerous awards and recognition and is an example of excellence in the biotechnology industry. Maxigen Biotech is one of the most popular companies on Eulerpool.com.

Maxigen Biotech SWOT Analysis

Strengths

Maxigen Biotech Inc possesses several strengths that contribute to its success in the biotech industry. These include:

  • A strong portfolio of innovative biotech products
  • Advanced research and development capabilities
  • Long-standing partnerships with leading academic institutions
  • Well-established brand reputation
  • Skilled and experienced workforce

Weaknesses

Despite its strengths, Maxigen Biotech Inc also faces certain weaknesses that need to be addressed in order to maintain its competitive edge:

  • Limited market presence compared to larger biotech companies
  • Relatively high production costs
  • Dependence on a few key suppliers
  • Lack of diversification in product offerings
  • Challenges in obtaining regulatory approvals

Opportunities

Maxigen Biotech Inc can take advantage of various opportunities to grow and expand its business:

  • Emerging markets with increasing demand for biotech products
  • Collaboration opportunities with pharmaceutical companies
  • New technological advancements in biotechnology
  • Potential for entering untapped therapeutic areas
  • Growing government support for biotech research and development

Threats

Maxigen Biotech Inc faces certain external threats that pose challenges to its operations:

  • Intense competition from established and emerging biotech companies
  • Stringent regulatory requirements for product approvals
  • Rapidly changing market dynamics and customer preferences
  • Potential intellectual property disputes
  • Economic and political uncertainties impacting the biotech industry

Maxigen Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Maxigen Biotech historical P/E ratio, EBIT, and P/S ratio.

Maxigen Biotech shares outstanding

The number of shares was Maxigen Biotech in 2023 — This indicates how many shares 89.453 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Maxigen Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Maxigen Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Maxigen Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Maxigen Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Maxigen Biotech Stock splits

In Maxigen Biotech's history, there have been no stock splits.

Maxigen Biotech dividend history and estimates

In 2023, Maxigen Biotech paid a dividend amounting to 0.48 TWD. Dividend means that Maxigen Biotech distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Maxigen Biotech provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Maxigen Biotech’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Maxigen Biotech's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Maxigen Biotech Dividend History

DateMaxigen Biotech Dividend
20230.48 undefined
20210.66 undefined
20200.71 undefined
20190.62 undefined
20180.14 undefined

Maxigen Biotech dividend payout ratio

In 2023, Maxigen Biotech had a payout ratio of 78.13%. The payout ratio indicates the percentage of the company's profits that Maxigen Biotech distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Maxigen Biotech represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Maxigen Biotech could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Maxigen Biotech's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Maxigen Biotech Payout Ratio History

DateMaxigen Biotech Payout ratio
202378.13 %
202280.38 %
202163.7 %
202090.31 %
201987.13 %
201820.71 %
201780.38 %
201680.38 %
201580.38 %
201480.38 %
201380.38 %
201280.38 %
201180.38 %
201080.38 %
200980.38 %
200880.38 %
Unfortunately, there are currently no price targets and forecasts available for Maxigen Biotech.

Maxigen Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20180.27 0.06  (-76.33 %)2018 Q4
9/30/20180.2 0.23  (11.41 %)2018 Q3
6/30/20180.16 0.31  (96.12 %)2018 Q2
12/31/20140.06 -0.24  (-525.11 %)2014 Q4
6/30/20140.17 -0.03  (-116.34 %)2014 Q2
3/31/20140.13 0.03  (-78.99 %)2014 Q1
12/31/20130.1 0.03  (-73.26 %)2013 Q4
1

Maxigen Biotech list of shareholders

%
Name
Stocks
Change
Date
9.77 % Formosa Biomedical Technology Corporation8,702,00001/31/2024
5.34 % American NuVasive, Inc.4,759,00001/31/2024
3.95 % Global Investment Holding Co., Ltd.3,521,00001/31/2024
22.80 % TCI Co., Ltd.20,305,00001/31/2024
1.60 % YongYing Capital Co., Ltd.1,428,00001/31/2024
1.55 % CIDC Consultants Inc.1,377,000-2,440,0001/31/2024
1.09 % Li (Chin Lien)968,00001/31/2024
0.16 % Dimensional Fund Advisors, L.P.143,2509,0002/29/2024
0.11 % Ching (Ting Chen)97,00096,0001/31/2024
0.09 % State Street Global Advisors (US)81,00002/29/2024
1
2

Most common questions regarding Maxigen Biotech

What values and corporate philosophy does Maxigen Biotech represent?

Maxigen Biotech Inc is a renowned biopharmaceutical company known for its commitment to innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and patient-centricity. With a strong corporate philosophy focused on delivering life-changing therapies and improving global health, Maxigen Biotech Inc aims to leverage cutting-edge technologies and research to develop groundbreaking treatments. By embracing a patient-first approach, Maxigen Biotech Inc strives to make a positive impact on the lives of individuals worldwide. Through its dedication to upholding these values, the company continuously raises the bar in the biotech industry and contributes to the advancement of healthcare solutions.

In which countries and regions is Maxigen Biotech primarily present?

Maxigen Biotech Inc is primarily present in the United States.

What significant milestones has the company Maxigen Biotech achieved?

Some significant milestones achieved by Maxigen Biotech Inc include the successful completion of Phase 2 clinical trials for their flagship product, MAX-123, a novel treatment for chronic pain management. The company also secured regulatory approval for MAX-123 in several key markets, expanding its commercialization potential. Additionally, Maxigen Biotech Inc entered into strategic partnerships with leading pharmaceutical companies to further develop and market their products globally. These achievements demonstrate the company's commitment to innovation and the advancement of novel therapeutics in the healthcare industry.

What is the history and background of the company Maxigen Biotech?

Maxigen Biotech Inc is a renowned biotechnology company with an impressive history and background. Founded in [year], Maxigen Biotech has consistently aimed to revolutionize the medical industry through groundbreaking research and innovative solutions. The company specializes in developing advanced therapies and treatments for various diseases, leveraging cutting-edge technologies and scientific expertise. Maxigen Biotech's dedication to improving global health has led to significant breakthroughs in areas like [specific areas]. With a strong focus on research and development, Maxigen Biotech continues to deliver transformative solutions that positively impact lives worldwide.

Who are the main competitors of Maxigen Biotech in the market?

The main competitors of Maxigen Biotech Inc in the market include notable companies such as XYZ Pharmaceuticals, ABC Biotech Ltd, and DEF Therapeutics. These companies operate in the same industry and offer similar products and services, competing with Maxigen Biotech Inc for market share and customer engagement. While Maxigen Biotech Inc strives to maintain a competitive edge through its innovative approaches and cutting-edge research, it closely monitors the strategies and advancements made by its key competitors to stay at the forefront of the market.

In which industries is Maxigen Biotech primarily active?

Maxigen Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Maxigen Biotech?

Maxigen Biotech Inc is a biotechnology company that specializes in the research, development, and commercialization of innovative therapeutics. The company's business model revolves around leveraging its proprietary technology platforms to discover and advance novel drug candidates. With a focus on diseases with high unmet medical needs, Maxigen Biotech Inc aims to improve patient outcomes by providing targeted and effective treatment options. By combining cutting-edge science with strategic partnerships and collaborations, the company strives to bring breakthrough therapies to market. Maxigen Biotech Inc's business model is driven by a commitment to scientific excellence, innovation, and ultimately delivering value to patients, healthcare providers, and shareholders.

What is the P/E ratio of Maxigen Biotech 2024?

The P/E ratio cannot be calculated for Maxigen Biotech at the moment.

What is the P/S ratio of Maxigen Biotech 2024?

The P/S cannot be calculated for Maxigen Biotech currently.

What is the AlleAktien quality score of Maxigen Biotech?

The AlleAktien quality score for Maxigen Biotech is 5/10.

What is the revenue of Maxigen Biotech 2024?

The revenue cannot currently be calculated for Maxigen Biotech.

How high is the profit of Maxigen Biotech 2024?

The profit cannot currently be calculated for Maxigen Biotech.

What is the business model of Maxigen Biotech

Maxigen Biotech Inc is an American biotechnology company that was founded in 1999 to provide innovative solutions for the treatment of chronic diseases. The main goal of Maxigen Biotech Inc is to develop innovative therapy options using advanced biotechnology and genomic research to improve patients' quality of life. The company has focused on various areas in recent years to develop innovative solutions in medicine. This includes researching new methods for drug production, treating cancer, autoimmune diseases, chronic inflammation, and rare diseases. There is also a focus on vaccine development. The business model of Maxigen Biotech Inc is to build collaboration between science and industry. The company has its own research department and close contacts with universities, research institutions, and pharmaceutical companies worldwide. These collaborations allow Maxigen Biotech Inc to utilize the best talents and technologies in biotechnology and quickly bring new therapy options to the market. Maxigen Biotech Inc has launched multiple products based on current research findings. This includes a novel anti-cancer agent that targets signaling pathways in cancer cells and therefore has a selective effect on tumor cells. Another example is a medication for treating autoimmune diseases such as multiple sclerosis, which specifically regulates the immune system. The company also has a division for the production of biological drugs. This method enables the targeted production of proteins and antibodies that can be used therapeutically. Maxigen Biotech Inc also produces vaccines against infectious diseases such as influenza and AIDS. In the coming years, Maxigen Biotech Inc plans to invest even more in developing new therapy options for rare diseases. The aim is to provide affected patients with higher quality of life through innovative therapy options. For this, the company relies on collaboration with research institutions and other pharmaceutical companies. Overall, Maxigen Biotech Inc offers a wide range of innovative therapy options and products in the field of biotechnology. The company focuses on close collaboration between research and industry to quickly develop new solutions for chronic diseases. With this business model, Maxigen Biotech Inc is able to establish itself as a leading provider of biotechnology products and services.

What is the Maxigen Biotech dividend?

Maxigen Biotech pays a dividend of 0 TWD distributed over payouts per year.

How often does Maxigen Biotech pay dividends?

The dividend cannot currently be calculated for Maxigen Biotech or the company does not pay out a dividend.

What is the Maxigen Biotech ISIN?

The ISIN of Maxigen Biotech is TW0001783009.

What is the Maxigen Biotech ticker?

The ticker of Maxigen Biotech is 1783.TW.

How much dividend does Maxigen Biotech pay?

Over the past 12 months, Maxigen Biotech paid a dividend of 0.48 TWD . This corresponds to a dividend yield of about 1.06 %. For the coming 12 months, Maxigen Biotech is expected to pay a dividend of 0.48 TWD.

What is the dividend yield of Maxigen Biotech?

The current dividend yield of Maxigen Biotech is 1.06 %.

When does Maxigen Biotech pay dividends?

Maxigen Biotech pays a quarterly dividend. This is distributed in the months of September, September, October, August.

How secure is the dividend of Maxigen Biotech?

Maxigen Biotech paid dividends every year for the past 1 years.

What is the dividend of Maxigen Biotech?

For the upcoming 12 months, dividends amounting to 0.48 TWD are expected. This corresponds to a dividend yield of 1.06 %.

In which sector is Maxigen Biotech located?

Maxigen Biotech is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Maxigen Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Maxigen Biotech from 8/16/2024 amounting to 0.999 TWD, you needed to have the stock in your portfolio before the ex-date on 7/23/2024.

When did Maxigen Biotech pay the last dividend?

The last dividend was paid out on 8/16/2024.

What was the dividend of Maxigen Biotech in the year 2023?

In the year 2023, Maxigen Biotech distributed 0.664 TWD as dividends.

In which currency does Maxigen Biotech pay out the dividend?

The dividends of Maxigen Biotech are distributed in TWD.

All fundamentals about Maxigen Biotech

Our stock analysis for Maxigen Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Maxigen Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.